#SumitomoPharma

Sumitomo Pharma has registered the issuance of new shares with an upper limit of 60,000,000 shares and 140 billion yen, planning to secure funds to promote the growth strategy 'Boost 2028.'

Sumitomo Pharma has formulated the growth strategy 'Boost 2028' covering fiscal years 2026 to 2028, aiming for over 350 billion yen in sales from Orgovix and Gemtesa, ROE above 10%, and equity ratio over 50% by fiscal 2028.

Sumitomo Pharma forecasts core sales of approximately 260 billion yen, core operating income of approximately 43 billion yen, and free cash flow of approximately 47 billion yen for FY2025, announcing a growth strategy targeting core product sales of 250 billion yen scale in the 2030s.

Revised the revenue for the fiscal year ending March 2026 to 449.0 billion yen (4.7% increase from previous forecast), operating income to 108.0 billion yen (10.2% increase), and net income attributable to owners of parent to 102.0 billion yen (10.9% increase).